Zhang, D.; Shah, N.J.; Cook, M.; Blackburn, M.; Serzan, M.T.; Advani, S.; Potosky, A.L.; Madhavan, S.; Belouali, A.; Atkins, M.B.;
et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109.
https://doi.org/10.3390/cancers13236109
AMA Style
Zhang D, Shah NJ, Cook M, Blackburn M, Serzan MT, Advani S, Potosky AL, Madhavan S, Belouali A, Atkins MB,
et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers. 2021; 13(23):6109.
https://doi.org/10.3390/cancers13236109
Chicago/Turabian Style
Zhang, Dongyu, Neil J. Shah, Michael Cook, Matthew Blackburn, Michael T. Serzan, Shailesh Advani, Arnold L. Potosky, Subha Madhavan, Anas Belouali, Michael B. Atkins,
and et al. 2021. "Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis" Cancers 13, no. 23: 6109.
https://doi.org/10.3390/cancers13236109
APA Style
Zhang, D., Shah, N. J., Cook, M., Blackburn, M., Serzan, M. T., Advani, S., Potosky, A. L., Madhavan, S., Belouali, A., Atkins, M. B., & Braithwaite, D.
(2021). Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers, 13(23), 6109.
https://doi.org/10.3390/cancers13236109